Full text is available at the source.
Abstract
The bispecific mRNA vaccine against Zika and dengue viruses achieved up to an 8-fold enhancement in neutralizing antibody titers compared to the standard vaccine.
- The bispecific vaccine integrates separate modules designed to enhance both B-cell and T-cell responses.
- The B-cell module combines Zika virus protein with a component that boosts antibody production.
- The T-cell module includes shared parts of both viruses to stimulate immune responses without increasing the risk of antibody-dependent enhancement.
- In tests with immunodeficient mice, the vaccine provided protection against both Zika and dengue virus infections.
- The developed vaccine may offer a new approach for dealing with multiple viruses that can cause similar immune complications.
Simplified